Effect of preoperative nabuliumab adjuvant chemotherapy on tumor marker levels in patients with early and middle stage non-small cell lung cancer
10.3760/cma.j.cn115455-20240530-00457
- VernacularTitle:术前纳武利尤单抗辅助化疗对早中期非小细胞肺癌患者肿瘤标志物水平的影响
- Author:
Zhen GAO
1
;
Peijiang CHANG
1
;
Xuan WANG
1
Author Information
1. 青岛市胶州中心医院胸外科，青岛 266300
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Antineoplastic combined chemotherapy protocols;
Nabuliumab;
Pulmonary lobectomy
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(4):294-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of preoperative nabuliumab adjuvant chemotherapy on tumor marker levels in patients with early and middle stage non-small cell lung cancer(NSCLC).Methods:Using a prospective study method, 106 patients with early and middle stage NSCLC patients who underwent pulmonary lobectomy at Jiaozhou Central Hospital of Qingdao from January 2019 to January 2021 were selected and divided into two groups according to a random number table method, with 53 patients in each group. The control group received preoperative adjuvant chemotherapy with docetaxel, while the observation group received preoperative adjuvant chemotherapy with nivolumab. The pathological response rate, tumor markers, disease-related indicators, adverse reactions, surgical conditions were compared between the two groups.Results:After treatment, the pathological remission rate in the observation group was higher than that in the control group: 69.81% (37/53) vs. 41.51% (22/53), there was statistical difference ( χ2 = 8.60, P<0.05). After treatment, the levels of serum thymidine kinase 1 (TK1), carbohydrate antigen 125, specific tissue polypeptide antigen and transforming growth factor beta 1, lactate dehydrogenase, vascular endothelial growth factor in the observation group were lower than those in the control group: (1.42 ± 0.37) pmol/L vs. (1.73 ± 0.42) pmol/L, (43.55 ± 4.19) kU/L vs. (47.85 ± 5.36) kU/L, (4.12 ± 1.05) μg/L vs. (6.85 ± 1.39) μg/L, (38.75 ± 5.85) μg/L vs. (43.72 ± 6.19) μg/L, (173.65 ± 15.37) U/L vs. (189.75 ± 20.18) U/L, (367.52 ± 14.35) ng/L vs. (393.47 ± 18.49) ng/L, there were statistical differences ( P<0.05). The incidence rate of diarrhea, nausea and vomiting, and bone marrow suppression in the observation group were lower than those in the control group: 11.32%(6/53) vs. 30.19%(16/53), 15.09%(8/53) vs. 43.40%(23/53), 22.64%(12/53) vs. 56.60%(30/53), there were statistical differences ( χ2 = 5.74, 10.26, 12.78, P<0.05). The R0 resection rate and the incidence of surgery-related adverse reactions between the two groups had no statistical differences ( P>0.05). Conclusions:Preoperative nivolumab based adjuvant chemotherapy can improve the treatment effect of early and middle stage NSCLC patients undergoing pulmonary lobectomy, regulate tumor marker levels, inhibit tumor progression, reduce the risk of gastrointestinal reactions and bone marrow suppression, and does not affect surgical treatment.
